Publications by authors named "Klaudio Rikani"
Article Synopsis
- A study evaluated the use and effectiveness of intravenous brivaracetam (BRV) in treating status epilepticus (SE) across 24 neurology units in Italy from March 2018 to June 2020.
- Out of 56 patients analyzed, BRV was effective in resolving seizures in 57% of cases, with a notable early response (within 6 hours) observed in 39% of patients.
- The findings suggest that BRV is a safe and beneficial treatment for SE, especially when administered early after the onset of seizures.
Introduction: Since the onset of the novel coronavirus pandemic, several neurological complications secondary to SARS-CoV-2 infection have been reported, affecting central nervous system, peripheral nervous system and neuromuscular junction.
Case Report: We present the case of a 77-year-old man who developed bulbar myasthenia gravis (MG) eight weeks after SARS-CoV-2 infection. The search for serum antibodies against the acetylcholine receptor and the muscle-specific tyrosine kinase (MuSK), performed by radioimmunoassay (RIA), and the search of low-density lipoprotein receptor-related protein 4 antibodies, performed by immunohistochemistry, resulted negative, while anti-MuSK antibodies were detected by cell-based assay (CBA).